EMA’s PRIME Process Could Be A Model For Tackling Pediatric Development Issues, Says Industry
Executive Summary
The EMA can learn from its existing processes to ensure that the EU Paediatric Regulation is implemented in a way that fits more naturally with the industry's product development process and allows for improved dialogue, EFPIA has suggested.
You may also be interested in...
EU Action Plan To Address Common Criticisms Of Paediatric Regulation
A wide-range of stakeholders at a European Medicines Agency workshop on how to improve the implementation of the EU Paediatric Regulation offered practical solutions to address the current shortcomings.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.